Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 1, 2005, Pages 85-90

  Harirforoosh, Sam ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

COX 1; COX 2; Kidney; NSAIDs; Urinary sodium excretion

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; FLURBIPROFEN; MELOXICAM; MOBICOX; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; ROFECOXIB; SODIUM;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FLOW RATE; MALE; MICTURITION; NEPHROTOXICITY; NONHUMAN; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; SODIUM URINE LEVEL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; MALE; MEMBRANE PROTEINS; POTASSIUM; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM; URODYNAMICS;

EID: 19944424481     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y04-129     Document Type: Conference Paper

References (27)

1. Ahmad, S.R., Kortepeter, C., Brinker, A., Chen, M., and Beitz, J. 2002. Renal failure associated with the use of celecoxib and rofecoxib. Drug. Saf. 25: 537-544.
2. Brater, D.C. 1999. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am. J. Med. 107: 65S-70S
3. Breyer, M.D., and Harris, R.C. 2001. Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 10: 89-98.
4. Canadian Pharmacists Association. 2003. Compendium of Pharmaceutical and Specialties. The Canadian Drug reference for health professionals. Canadian Pharmacists Association, Ottawa.
5. Catella-Lawson, F., McAdam, B., Morrison, B.W., Kapoor, S., Kujubu, D., Antes, L. et al. 1999. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289: 735-741.
6. Chan, C.C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D. et al. 1999. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3- phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290: 551-560.
7. Dellinger, P., Murphy, T., Pinn, V., Barza, M., and Weinstein, L. 1976. Protective effect of cephalothin against gentamincin-induced nephrotoxicity in rats. Antimicrob. Agents Chemother. 9: 172-178.
8. Depre, M., Ehrich, E., Van Hecken, A., De Lepeleire, I., Dallob, A., Wong, P. et al. 2000. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. J. Clin. Pharmacol. 56: 167-174.
9. Dilger, K., Herrlinger, C., Peters, J., Seyberth, H.W., Schweer, H., and Klotz, U. 2002. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J. Clin. Pharmacol. 42: 985-994.
10. Gotoh, S., Ogihara, T., Nakamaru, M., Higaki, J., Ohde, H., Tabuchi, Y. et al. 1983. Effect of captopril on renal vascular resistance, renin, prostaglandins and kinin in the isolated perfused kidney. Life. Sci. 33: 2409-2415.
11. Hal, T., and Neilson, K. 1992. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388.
12. Halpin, R.A., Geer, L.A., Zhang, K.E., Marks, T.M., Dean, D.C., Jones, A.N. et al. 2000. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab. Dispos. 28: 1244-1254.
13. Kadokawa, T., Hosoki, K., Takeyama, K., Minato, H., and Shimizu, M. 1979. Effects of nonsteroidal anti-inflammatory drugs (NSAID) on renal excretion of sodium and water, and on body fluid volume in rats. J. Pharmacol. Exp. Ther. 209: 219-224.
14. Khan, K.N., Venthrini, C.M., Bunch, R.T., Brassard, J.A., Koki, A.T., Morris, S.L. et al. 1998. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol. Pathol. 26: 612-620.
15. Komhoff, M., Jeck, N.D., Seyberth, H.W., Grone, H.J., Nusing, R.M., and Breyer, M.D. 2000. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney. Int. 57: 414-422.
16. Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y. et al. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384: 644-648.
17. Schentag, J.J., Jusko, W.J., Plaut, M.E., Cumbo, T.J., Vance, J.W., and Abrutyn, E. 1977. Tissue persistence of gentamicin in man. JAMA, 238: 327-329.
18. Schwartz, J.I. Vandormael, K., Malice, M.P., Kalyani, R.N., Lasseter, K.C., Holmes, G.B. et al. 2002. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin. Pharmacol. Ther. 72: 50-61.
19. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A. et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284: 1247-1255.
20. Smith, W.L., and DeWitt, D.L. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. Adv. Immunol. 62: 167-215.
21. Svendsen, K.B., Bech, J.N., Sorensen, T.B., and Pedersen, E.B. 2000. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur. J. Clin. Pharmacol. 56: 383-388.
22. Takano, T., Cybulsky, A.V., Cupples, W.A., Ajikobi, D.O., Papillon, J., and Aoudjit, L. 2003. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J. Pharmacol. Exp. Ther. 305: 240-249.
23. Vane, J.R., Bakhe, T.S., and Bolting, R.M. 1998. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38: 97-110.
24. Vio, C.P., Cespedes, C., Gallardo, P., and Masferrer, J.L. 1997. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension, 30: 687-692.
25. Warner, T.D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J.A., and Vane, J.R. 1999. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA, 96: 7563-7568.
26. Watanabe, A., Nagai, J., Adachi, Y., Katsube, T., Kitahara, Y., Murakami, T., and Takano, M. 2004. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J. Control Release, 95: 423-433.
27. Zhao, S.Z., Reynolds, M.W., Lejkowith, J., Whelton, A., and Arellano F.M. 2001. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin. Ther. 23: 1478-1491.